DRW Securities LLC Makes New $62,000 Investment in Savara Inc (NASDAQ:SVRA)

DRW Securities LLC bought a new stake in shares of Savara Inc (NASDAQ:SVRA) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,492 shares of the company’s stock, valued at approximately $62,000.

A number of other institutional investors have also recently made changes to their positions in SVRA. Wellington Management Group LLP purchased a new stake in Savara during the fourth quarter valued at approximately $9,683,000. Opaleye Management Inc. bought a new stake in Savara in the first quarter worth $4,258,000. Superstring Capital Management LP purchased a new position in Savara during the fourth quarter worth $3,827,000. Janus Henderson Group PLC increased its position in Savara by 41.1% during the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after acquiring an additional 746,407 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC raised its stake in shares of Savara by 2.3% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock valued at $72,536,000 after acquiring an additional 332,706 shares during the period. Institutional investors own 87.93% of the company’s stock.

Savara Stock Down 4.1 %

Shares of NASDAQ SVRA opened at $4.42 on Wednesday. Savara Inc has a 52-week low of $3.12 and a 52-week high of $5.70. The firm has a market capitalization of $610.80 million, a price-to-earnings ratio of -11.95 and a beta of 0.97. The stock has a 50 day moving average price of $4.37 and a 200 day moving average price of $4.47. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31.

Savara (NASDAQ:SVRA) last issued its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Sell-side analysts expect that Savara Inc will post -0.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on SVRA shares. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Monday, September 9th. Oppenheimer increased their price target on Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a report on Wednesday, June 26th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Savara in a report on Wednesday, August 14th. Finally, Guggenheim increased their target price on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Savara currently has an average rating of “Buy” and an average target price of $11.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.